Using a new type of immune cell therapy to prevent and treat kidney transplant rejection
Investigating a Novel Cellular Therapy to Prevent and Treat Acute Antibody Mediated Kidney Transplant Rejection
This study is exploring a new type of immune cell that could help prevent kidney transplant rejection by stopping harmful antibodies, and it's designed for people who have received a kidney transplant and want to improve their chances of success.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10653007 on NIH RePORTER |
What this research studies
This research investigates a novel type of immune cell, known as CD8+ TAb-supp cells, which can suppress the production of harmful antibodies that lead to kidney transplant rejection. The study aims to enhance the development of these cells and assess their effectiveness in preventing and treating acute antibody-mediated rejection (AMR) in kidney transplant recipients. By conducting pre-clinical studies using a mouse model that mimics human kidney transplant conditions, the researchers hope to establish a new therapeutic approach that could improve transplant outcomes. The team consists of experts in transplantation and immunology, ensuring a comprehensive approach to the problem.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received a kidney transplant or are scheduled to undergo kidney transplantation.
Not a fit: Patients who have not undergone kidney transplantation or those with conditions unrelated to transplant rejection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved kidney transplant survival rates and better long-term outcomes for patients.
How similar studies have performed: Previous research has shown promise in using cellular therapies for transplant rejection, but this specific approach is novel and has not been extensively tested.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Bumgardner, Ginny L — Ohio State University
- Study coordinator: Bumgardner, Ginny L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.